Quest Diagnostics Inc.
Congress has disclosed 16 buys and 19 sells of DGX (Quest Diagnostics Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying DGX and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Rohit Khanna | 2024-11-15 | $154.86 | $251.82 | +62.6% | in profit |
| Alan Armstrong | 2026-03-30 | $194.78 | $251.82 | +29.3% | in profit |
Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
how it's calculated
Legislation Related Legislation
Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
35 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | BUY ◆ insider divergence | Self | 2026-03-30 | 113 days | +5.8% | $1K–$15K | 95.4 | ↗ eFD |
| Alan Armstrong | Senate | BUY ◆ insider divergence | Self | 2026-03-27 | 116 days | +6.7% | $1K–$15K | 99.1 | ↗ eFD |
| Julie Johnson | House | SELL ◆ insider convergence | Joint · Merrill Lynch Long Term Growth | 2025-11-03 | 37 days | +0.4% | $1K–$15K <0.1% of NW |
13.3 | ↗ filing |
| Julie Johnson | House | SELL ◆ insider convergence | Joint · Merrill Lynch Tax Efficient Core | 2025-10-30 | 7 days | +0.4% | $1K–$15K <0.1% of NW |
63.1 | ↗ filing |
| Julie Johnson | House | BUY ◆ insider divergence | Joint · Merrill Lynch Long Term Growth | 2025-10-30 | 7 days | +0.4% | $1K–$15K <0.1% of NW |
63.1 | ↗ filing |
| Julia Letlow | House | SELL ◆ insider convergence | Self · Merrill Lynch Investment Account #025 | 2025-07-24 | 18 days | +3.8% | $1K–$15K 1.0% of NW |
32.4 | ↗ filing |
| Julia Letlow | House | BUY ◆ insider divergence | Self · Merrill Lynch Investment Account #025 | 2025-04-28 | 105 days | +1.4% | $1K–$15K 1.0% of NW |
66.0 | ↗ filing |
| Carol Devine Miller | House | SELL ◆ insider convergence · moderate | Self · United Bank Brokerage Account | 2025-03-10 | 32 days | -4.8% | $15K–$50K 0.1% of NW |
92.4 | ↗ filing |
| Carol Devine Miller | House | SELL ◆ insider convergence · moderate | Self · Matt Miller Investment Management Account | 2025-03-10 | 32 days | -4.8% | $1K–$15K <0.1% of NW |
84.5 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2024-11-15 | 19 days | -0.1% | $1K–$15K | 22.3 | ↗ filing |
| Earl Blumenauer | House | SELL ◆ insider convergence | Spouse | 2024-04-04 | 29 days | — | $1K–$15K 0.1% of NW |
7.6 | ↗ filing |
| Rohit Khanna | House | BUY OCR | Child | 2023-12-05 | 30 days | — | $1K–$15K | 40.4 | ↗ filing |
| Rohit Khanna | House | BUY OCR | Spouse | 2023-12-04 | 31 days | — | $1K–$15K | 75.9 | ↗ filing |
| Carol Devine Miller | House | BUY | Self | 2022-11-14 | 21 days | — | $1K–$15K <0.1% of NW |
98.8 | ↗ filing |
| Kathy Manning | House | SELL | Joint · Charles Schwab - O'Shaughnessy Asset Management | 2022-08-03 | 34 days | — | $1K–$15K 0.1% of NW |
40.4 | ↗ filing |
| Kathy Manning | House | BUY | Joint · Charles Schwab - O'Shaughnessy Asset Management | 2022-07-20 | 13 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Earl Blumenauer | House | SELL | Self | 2022-03-14 | 0 days | — | $1K–$15K 0.1% of NW |
22.3 | ↗ filing |
| Earl Blumenauer | House | BUY | Self | 2022-02-24 | 18 days | — | $1K–$15K 0.1% of NW |
40.4 | ↗ filing |
| Sara Jacobs | House | SELL | Self | 2021-04-09 | 32 days | — | $50K–$100K 0.1% of NW |
94.3 | ↗ filing |
| Dean Phillips | House | SELL | Self | 2020-06-01 | 35 days | — | $1K–$15K <0.1% of NW |
5.5 | ↗ filing |
| Dean Phillips | House | SELL | Self | 2020-04-02 | 34 days | — | $1K–$15K <0.1% of NW |
6.8 | ↗ filing |
| Earl Blumenauer | House | BUY | Spouse | 2020-03-02 | 31 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Dean Phillips | House | SELL | Self | 2020-02-10 | 25 days | — | $1K–$15K <0.1% of NW |
8.6 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2020-01-17 | 19 days | — | $1K–$15K <0.1% of NW |
10.6 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2019-07-31 | 10 days | — | $1K–$15K <0.1% of NW |
15.7 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2019-05-03 | 35 days | — | $1K–$15K <0.1% of NW |
22.3 | ↗ filing |
| Dean Phillips | House | SELL | Self | 2019-04-04 | 41 days | — | $1K–$15K <0.1% of NW |
40.4 | ↗ filing |
| Gilbert Cisneros | House | BUY | Self | 2019-03-14 | 26 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2019-02-04 | 31 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Michael Conaway | House | SELL | Spouse | 2016-09-12 | 3 days | — | $1K–$15K | 75.9 | ↗ filing |
| Lois Frankel | House | SELL | Self | 2016-06-20 | 0 days | — | $1K–$15K 0.3% of NW |
40.4 | ↗ filing |
| Lois Frankel | House | SELL | Self | 2015-05-27 | 0 days | — | $1K–$15K 0.3% of NW |
75.9 | ↗ filing |
| Richard Hanna | House | SELL | Joint | 2014-10-15 | 22 days | — | $1K–$15K | 22.3 | ↗ filing |
| Richard Hanna | House | SELL | Self | 2013-12-30 | 10 days | — | $1K–$15K | 40.4 | ↗ filing |
| Richard Hanna | House | SELL | Self | 2013-12-27 | 13 days | — | $100K–$250K | 96.7 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in DGX — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in DGX, 6 coincided with corporate insiders moving the same way within 60 days, and 5 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-26 | PFEIFFER GARY M | Director | SELL 10b5-1 | $292K | ↗ EDGAR |
| 2026-09-01 | Davis J. E. | C-suite | SELL 10b5-1 | $2.4M | ↗ EDGAR |
| 2026-08-28 | PREVOZNIK MICHAEL E | Other | SELL 10b5-1 | $3.9M | ↗ EDGAR |
| 2026-08-28 | PREVOZNIK MICHAEL E | Other | SELL 10b5-1 | $1.5M | ↗ EDGAR |
| 2026-08-28 | PREVOZNIK MICHAEL E | Other | SELL 10b5-1 | $105K | ↗ EDGAR |
| 2026-07-28 | DELANEY MARK E | C-suite | SELL 10b5-1 | $376K | ↗ EDGAR |
| 2026-06-04 | KUPPUSAMY KARTHIK | Other | SELL 10b5-1 | $1.6M | ↗ EDGAR |
| 2026-06-01 | Davis J. E. | C-suite | SELL 10b5-1 | $1.9M | ↗ EDGAR |
| 2026-03-05 | Plewman Patrick | Other | SELL 10b5-1 | $589K | ↗ EDGAR |
| 2026-03-05 | PREVOZNIK MICHAEL E | Other | SELL 10b5-1 | $800K | ↗ EDGAR |
| 2026-03-05 | Doherty Catherine T. | Other | SELL 10b5-1 | $1.1M | ↗ EDGAR |
| 2026-03-04 | KUPPUSAMY KARTHIK | Other | SELL | $538K | ↗ EDGAR |
| 2026-03-03 | Plewman Patrick | Other | SELL 10b5-1 | $85K | ↗ EDGAR |
| 2026-03-03 | PREVOZNIK MICHAEL E | Other | SELL 10b5-1 | $109K | ↗ EDGAR |
| 2026-03-03 | Doherty Catherine T. | Other | SELL 10b5-1 | $131K | ↗ EDGAR |
| 2026-03-02 | Davis J. E. | C-suite | SELL 10b5-1 | $2.1M | ↗ EDGAR |
| 2026-02-19 | PREVOZNIK MICHAEL E | Other | SELL 10b5-1 | $228K | ↗ EDGAR |
| 2026-02-19 | Plewman Patrick | Other | SELL 10b5-1 | $196K | ↗ EDGAR |
| 2026-02-19 | Doherty Catherine T. | Other | SELL 10b5-1 | $294K | ↗ EDGAR |
| 2026-02-13 | Doherty Catherine T. | Other | SELL 10b5-1 | $2.2M | ↗ EDGAR |
| 2026-02-13 | Doherty Catherine T. | Other | SELL 10b5-1 | $2.1M | ↗ EDGAR |
| 2026-02-13 | Doherty Catherine T. | Other | SELL 10b5-1 | $725K | ↗ EDGAR |
| 2026-02-13 | Doherty Catherine T. | Other | SELL 10b5-1 | $337K | ↗ EDGAR |
| 2026-02-13 | Doherty Catherine T. | Other | SELL 10b5-1 | $73K | ↗ EDGAR |
| 2026-02-10 | Plewman Patrick | Other | SELL 10b5-1 | $1.2M | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-26 | PFEIFFER GARY M Director 10b5-1 | SELL | $292K |
| ◆ insider | 2026-09-01 | Davis J. E. C-suite 10b5-1 | SELL | $2.4M |
| ◆ insider | 2026-08-28 | PREVOZNIK MICHAEL E Other 10b5-1 | SELL | $3.9M |
| ◆ insider | 2026-08-28 | PREVOZNIK MICHAEL E Other 10b5-1 | SELL | $1.5M |
| ◆ insider | 2026-08-28 | PREVOZNIK MICHAEL E Other 10b5-1 | SELL | $105K |
| ◆ insider | 2026-07-28 | DELANEY MARK E C-suite 10b5-1 | SELL | $376K |
| ◆ insider | 2026-06-04 | KUPPUSAMY KARTHIK Other 10b5-1 | SELL | $1.6M |
| ◆ insider | 2026-06-01 | Davis J. E. C-suite 10b5-1 | SELL | $1.9M |
| Congress | 2026-03-30 | Alan Armstrong | BUY | $1K–$15K |
| Congress | 2026-03-27 | Alan Armstrong | BUY | $1K–$15K |
| ◆ insider | 2026-03-05 | Plewman Patrick Other 10b5-1 | SELL | $589K |
| ◆ insider | 2026-03-05 | PREVOZNIK MICHAEL E Other 10b5-1 | SELL | $800K |
| ◆ insider | 2026-03-05 | Doherty Catherine T. Other 10b5-1 | SELL | $1.1M |
| ◆ insider | 2026-03-04 | KUPPUSAMY KARTHIK Other | SELL | $538K |
| ◆ insider | 2026-03-03 | Plewman Patrick Other 10b5-1 | SELL | $85K |
| ◆ insider | 2026-03-03 | PREVOZNIK MICHAEL E Other 10b5-1 | SELL | $109K |
| ◆ insider | 2026-03-03 | Doherty Catherine T. Other 10b5-1 | SELL | $131K |
| ◆ insider | 2026-03-02 | Davis J. E. C-suite 10b5-1 | SELL | $2.1M |
| ◆ insider | 2026-02-19 | PREVOZNIK MICHAEL E Other 10b5-1 | SELL | $228K |
| ◆ insider | 2026-02-19 | Plewman Patrick Other 10b5-1 | SELL | $196K |
| ◆ insider | 2026-02-19 | Doherty Catherine T. Other 10b5-1 | SELL | $294K |
| ◆ insider | 2026-02-13 | Doherty Catherine T. Other 10b5-1 | SELL | $2.2M |
| ◆ insider | 2026-02-13 | Doherty Catherine T. Other 10b5-1 | SELL | $2.1M |
| ◆ insider | 2026-02-13 | Doherty Catherine T. Other 10b5-1 | SELL | $725K |
FAQ Common questions
How much has Congress traded DGX?
16 disclosed buys and 19 sells of DGX (Quest Diagnostics Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade DGX?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.